Conferences

International BioDelivery Sciences, Incorporation (Nasdaq: BDSI) announced that four scientific posters for its product of the linking, fentanyl™ of BEMA, currently under the revision for the administration of the food and the drug of United States (FDA) as a potential treatment for the pain of the discovery (BTP) in opioid-tolerant patients with cancer, will be presented in 27a annual scientific meeting of the American society of pain (APS), May 8-10, in Cover, Flowery. The scientific presentations will detach efficacy of phase III and the data of security as.well.as pharmacokinetics of fentanyl™ of BEMA. The posters will be presented May 8 and in 9.

In January, sciences of BioDelivery had announced that the FDA accepted filing the new application of the drug of the company (NDA) for fentanyl™ of BEMA. Sciences of BioDelivery anticipate a formal decision in the NDA August for 31, 2008. In America of the North and Europe, the commercial right to fentanyl™ of BEMA are permitted Haystack AB.

Posters indicated in thursday, May 8, of 4:45 p.m. the 6:15 p.m. EDT:

- “efficient control fast e of the pain and tolerability of the discovery in patients of cancer dealt with with fentanyl™ BEMA,” the north of James, MD, main investigator for the study of efficacy of phase III

- of the “linearities absolute dose and bioavailability of fentanyl™ of BEMA in healthful volunteers,” Niraj Vasisht, vice-president, development of product, sciences of BioDelivery

Posters indicated in friday, May 9, of 4:00 p.m. the 5:30 p.m. EDT:

- “the security of the use™ of fentanyl of BEMA for the pain of the discovery in patients of cancer,” Neal F. Slatkin, medical director, department of the care of support, pain and palliative medicine, city of the national medical center of the hope

- “adverse events that affect the mouth in three clinical experimentations of fentanyl™ of BEMA,” David Blum, MD, medical vice-president, cases and clinical research, sciences of BioDelivery

Sciences of BioDelivery invite members of the ways and the scientific community to program in advance confidential meetings with connoisseurs of the company and the main investigator of the study of efficacy of phase III for the brown being contacted of Stephanie in stephanie.brown@fdashtonpartners.com.

On International SciencesBioDelivery

International BioDelivery Sciences, Incorporation is a pharmaceutical company of specialty that it is focused in developing innovative products to direct the increasing chances of the market, including conditions such as pain. The company uses its patented technologies of the delivery of the drug to become, partner possessed and permitted, and commercialize new products using therapeutics proven. Franchise of the BDSI pain consists currently of two products in the development that uses the patented verbal technology of the adhesive™ film of BEMA of the company: Fentanyl™ of BEMA, a potential treatment for the pain of the “discovery” in tolerant patients of opioid with cancer (NDA currently under the revision for FDA), and BEMA™ Buprenorphine, as analgesic with the o but a potential indication of the target for the treatment of moderate to severe pain. The company is working with its technology™ of BEMA and its technology cochleate(R) patented of Bioral in the products whitened in the common circumstances to oncology and the surgical patients such as pain and the infections. The matrices of the company are been situated in Raleigh, North.carolina, and its main laboratory is been situated in Newark, Novo-Jersey. For more information it visits http://www.bdsinternational.com please.

For Diante-Olhando Indications

Note: To the exception of the contained historical information in this, of this release of the press and the indications of the representatives and the partners of International BioDelivery Sciences, Incorporation (”company”) related to this contains or can contain, among others things, definitive indications for ahead-looking at, inside of meaning of the confidential act of the reform of litigation of seguranas of 1995. Such indications for ahead-looking at involve significant risks and uncertainties. Such indications can include, without limitation, indications with respect to the plants of the company, objectives, projections, expectations and the intentions and other indications identified for words such as “projects”, “can”, “could”, “”, “if”, “it believes”, “it waits”, “it anticipates”, “it esteem”, “it intends”, “similar planeia” or expressions.

These indications are based on the opinion and the current expectations of the management of the company and are citizens to the risks and the significant uncertainties, including those detailed in the fillings of the company with commission of seguranas and exchange. Real results, including, without limitation: (i) the real results of vendas and royalty or the payments of the noticeable landmark, if to exister, (ii) the programmed clinical experimentations or you add the necessity and and to the incorporated deep application availability of the company for deep of the future, or (iii) the synchronism for the conclusion, and of the results of, and fDA or to another revision and/or aprova0 regulatory and commercial launching of formulations of the company and the products and the fillings regulatory if to relate exactly, can differ significantly from those definitive ones in the indications for ahead-looking at. These indications for ahead-looking at involve the definitive risks and uncertainties that are citizens to the change based on the some factors (many of that they are beyond the control of the company). Vendas and the estimates peak of the size of market had been determined in the base of the research of market and the analysis of comparable product, but no guarantee can be given that such levels of vendas will be obtained, if in everything.

International SciencesBioDelivery